Afayro 20mg Tablet

Afayro 20mg Tablet

Prescription requiredRx Required

Salt Composition: Afatinib

Expiry Date: 01/2028

Special offer

Buy at $59.56

$59.56

Inclusive of all taxes

28

About The Product

Lung Cancer, monotherapy

Description

Afayro 20mg tablet is used in the treatment of non-small cell lung cancer (NSCLC) whose tumor show particular mutations in Epidermal growth factor (EGFR), the medication directly targeting this mutation caused enzyme and preventing them from multiplying, slowing tumor growth and helping to control the progression of the disease. The medication active ingredient is Afatinib and belongs to the class of anti-cancer medication known as tyrosine kinase inhibitor.

Doctor prescribed this medication as a part of a targeted therapy plan to inhibit cancer cell growth in patients with EGFR mutated NSCLC.

Indication

Non small cell lung cancer

Common side effects

Like every other medication Afayro 20mg tablet also show various side effects, also not everyone experience them but consult the doctor if any of these are persist:
● Interstitial lung disease (ILD)
● Severe diarrhea or dehydration
● Liver problems
● Eye problems, such as corneal erosion or ulceration
● Hemorrhage or bleeding problems
● Kidney problems
● Cardiac problems
● Diarrhea
● Mouth sores
● Acne or skin rash
● Nausea and vomiting
● Fatigue

Dosage and administration

  • Afayro 20mg tablet is an oral medication designed to take it on an empty stomach at the same time everyday to enhance the effectiveness of the treatment.
  • Do not miss a dose but if you do then skip the missed dose and continue with the regular schedule.
  • Doctor will guide you better about the dose and duration based on the patient's medical history.
  • It is important to follow all the medical instructions carefully and repost any unusual side effects the healthcare provider.

Mechanism of action

EGFR is an enzyme in the human body which is responsible for the growth of cancer cells. Afayro 20mg tablet is an anticancer drug that specifically targets the EGFR mutated gene and binding that.

Hence, it stops the production of tumor cells, thereby slowing or stopping the production of cancer cells and preventing the body from further growing cancer in the body.

Safety advice

Alcohol
Patients who are taking Afayro 20mg tablet should avoid taking alcohol as it may interfere with the effectiveness of the treatment.
Driving
It is not known if Afayro 20mg tablet caused dizziness but do not drive if you experience any side effects.
Pregnancy
Pregnant women should avoid using Afayro 20mg, as it may harm the developing baby.
Breast Feeding
Afayro 20mg tablet is not used by the women who breastfeed their child because drug may pass into breast milk and potentially harm the baby.
Kidney
Afayro 20mg tablet is safe for kidney patient but taken under doctor prescription is better to ensure safe and effectiveness of the medication.
Liver
Afayro tablet is probably safe to use liver patient but still doctor guidance is much needed for proper treatment.

FAQs

Afayro 20mg tablet should be taken on an empty stomach at the same time everyday without skipping a single dose to make the treatment effective.

Do not crush or chew tablet, just take it with a glass of water.

Reference

• WAEC, N., & a Doctor, C. Cytogard 20mg Tablet 10?

S. • Park, K., Tan, E. H., O'Byrne, K., Zhang, L., Boyer, M., Mok, T., ... & Paz-Ares, L.

(2016). Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.

The Lancet Oncology, 17(5), 577-589. • Solca, F., Dahl, G., Zoephel, A., Bader, G., Sanderson, M., Klein, C., ... & Adolf, G. R.

(2012). Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker.

The Journal of pharmacology and experimental therapeutics, 343(2), 342-350. • Harvey, R. D., Adams, V.

R., Beardslee, T., & Medina, P. (2020).

Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings. Journal of Oncology Pharmacy Practice, 26(6), 1461-1474. • Schuler, M., Yang, J.

H., Park, K., Kim, J. H., Bennouna, J., Chen, Y.

M., ... & Popovych, O. (2016).

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Annals of Oncology, 27(3), 417-423.

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Magicine PharmacopyCopyright 2026